Search results
Showing 2731 to 2745 of 9098 results
We are listening to your views on this HealthTech guidance. Comments close 6 July 2026.
In development Reference number: GID-HTG10868 Expected publication date: 15 September 2026
Deucravacitinib for treating systemic lupus erythematosus [TSID12405]
Awaiting development Reference number: GID-TA12035 Expected publication date: TBC
Awaiting development Reference number: GID-TA12030 Expected publication date: TBC
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults
Summary of the evidence on desflurane for maintenance of anaesthesia
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)
Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making